ONE of the Most Impactful Meetings in Rare Cancer Research - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/voices/vivek... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

2. Need structured approaches for how to evaluate even when an ultra-specific histology driven approach isn't feasible, as @viveksubbiah.bsky.social outlines for rare cancers here: ascopubs.org/doi/10.1200/...

Read the Cancer Discovery Piece: Rethinking Cancer Drug Development through Tumor-Agnostic Precision Medicine by @viveksubbiah.bsky.social doi.org/10.1158/2159...

ESMO 2025 - Catalyzing Novel Collaborations for Global Impact in Oncology - Vivek Subbiah @viveksubbiah.bsky.social @myesmo.bsky.social oncodaily.com/voices/esmo-... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO25

Honored to Present at ESMO Annual Meeting Young Oncologists Clinical Case Discussions - Vivek Subbiah @viveksubbiah.bsky.social @myesmo.bsky.social oncodaily.com/voices/vivek... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Precision Oncology and Modernizing Evidence Standards - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/voices/vivek... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

ESMO Presidential Dinner is Kicking Off in Berlin - Vivek Subbiah @viveksubbiah.bsky.social @myesmo.bsky.social oncodaily.com/voices/vivek... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025

Rethinking Cancer Drug Development Through Tumor-Agnostic Precision Medicine - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/voices/vivek... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025

Great #ESMO25 talk by @viveksubbiah.bsky.social on targeting molecular drivers of cancer in a tissue-agnostic manner: for more of his thoughts, check out his @aacrjournals.bsky.social Cancer Discovery piece (online as of October 17) here:

Smarter Trial Designs: How Project Optimus is Changing Early-Phase Cancer Research - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/voices/vivek... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

D-7 until #ESMO25! 👋🇩🇪 Excited to be part of first ever tumor-agnostic scientific track with @viveksubbiah.bsky.social @JulianaRBeale #NiamhColeman Don’t miss these educational sessions! ⬇️ @myesmo.bsky.social

Impact of FDA Project Optimus Guidance on Early-Phase Trial Design - Vivek Subbiah @viveksubbiah.bsky.social @fda.gov oncodaily.com/voices/vivek... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/voices/vivek... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

⭐️When AI rejects your grant proposal: algorithms are helping to make funding decisions A foundation using an AI tool to screen grant applications says it makes the peer-review process more efficient, but other researchers say it’s a breakdown in trust www.nature.com/articles/d41...

Appropriately critical commentary on cochrane reviews as the apply to matched targeted therapy by @viveksubbiah.bsky.social Journal of Clinical Oncology ascopubs.org/doi/full/10....

PFS benefit noted with adagrasib

10 Must-Read Posts in Immuno-Oncology This Week @viveksubbiah.bsky.social @jiajennyliu.bsky.social @gerryhanna.bsky.social @drjnaidoo.bsky.social oncodaily.com/oncolibrary/... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #IO #ImmuneOncology

Nature Medicine Study on Molecular Profiling in Meningioma - @viveksubbiah.bsky.social oncodaily.com/science/vive... #OncoDaily #Oncology #Cancer #Health #Medicine

Rare Cancers Deserve Breakthroughs Too - Vivek Subbiah @viveksubbiah.bsky.social @conquercancer.bsky.social oncodaily.com/blog/rare-ca... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Top Articles Suggested by Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/voices/vivek... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

🔊 Listen to Jiyoung Ahn, PhD, of New York University, discuss with @viveksubbiah.bsky.social, MD, about whether the oral bacterial and fungal microbiome is associated with the development of pancreatic #cancer. Listen now: ja.ma/41Vzuh9

Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center - Vivek Subbiah @viveksubbiah.bsky.social @fredhutch.org oncodaily.com/career/vivek... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Top 5 Articles of the Week Suggested by Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/voices/vivek... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial - The Lancet www.thelancet.com/journals/lan...

Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study - The Lancet Oncology www.thelancet.com/journals/lan...

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol - The Lancet Oncology www.thelancet.com/journals/lan...

What is Missing to Fully Harness Precision Medicine and Transform Cancer Care - Vivek Subbiah @viveksubbiah.bsky.social @natmed.nature.com oncodaily.com/blog/vivek-s... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PrecisionMedicine

It’s Time We Evolve WHO Cancer Classification - Vivek Subbiah @viveksubbiah.bsky.social @who.int oncodaily.com/science/vive... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerClassification #WHO

How Clinical Trials Offer Hope for Those Facing Limited Options - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/blog/clinica... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ClinicalTrial #Sarcoma #SarcomaAwarenessMonth

⭐️Tissue-agnostic cancer therapies: promise, reality, and the path forward @natcomms.nature.com @ascocancer.bsky.social #ASCO25 www.nature.com/articles/s41...

🚨 Hot off the press! 🚨 The @myesmo.bsky.social ESMO Precision Oncology Working Group, has unveiled key "Recommendations for structuring Molecular Tumour Boards (MTBs) in clinical practice", now published in ESMO's flagship journal Annals of Oncology 🧬🏥 www.annalsofoncology.org/article/S092...

Cancer Isn’t Just a Human Disease – It’s a Biological Reality Across Species, From Dogs to Tigers to the Extinct Dinosaurs - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/blog/vivek-s... #OncoDaily #Oncology #Cancer #Medicine #Health

25 Posts Not to Miss from EHA 2025 @nicogagelmann.bsky.social @talhabadarmd.bsky.social @majorajay.bsky.social @vincentrk.bsky.social @viveksubbiah.bsky.social @nejm.org oncodaily.com/societies/eh... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EHA2025 #EHA25

Why Every Rare Cancer Patient Deserves Molecular Profiling? - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/insight/vive... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #RareCancers #MolecularProfiling

Super interesting. "Tissue-agnostic #cancer therapies promise 2 revolutionize oncology by targeting molecular drivers. [A] study of nearly 300K tumors found 21.5% w/tissue-agnostic indications. Despite 9 #FDA approvals, real-world implementation challenges ..." 1/2 #CanSky #OncSky #ASCO25

⭐️Tissue-agnostic cancer therapies: promise, reality, and the path forward @natcomms.nature.com @ascocancer.bsky.social #ASCO25 www.nature.com/articles/s41...

ASCO and Google create ‘walled garden’ AI tool for doctors to query group’s guidelines www.statnews.com/2025/05/21/a... via @statnews.com

Honored to Work Alongside an Incredible Team of Investigators Dedicated to Ending Cancer - Vivek Subbiah @viveksubbiah.bsky.social oncodaily.com/blog/team-of... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ClinicalTrialsDay #ASCO25

Inspiring Journey of the 2024 Yvonne Awardees - A Year of Impact and Leadership @drasyaagulnik.bsky.social @viveksubbiah.bsky.social oncodaily.com/blog/yvonne-... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Yvonne #Leadership

⭐️To all the incredible moms who fill our lives with love, strength, and wisdom-today is for you. 🙏🏽Thank you for being the heart of every home & the foundation of so many dreams. Happy Mother’s Day! 💐❤️ #MothersDay

Exhilarating discussions on new podcast: Immunoverse - Vivek Subbiah @viveksubbiah.bsky.social @patrickhwumd.bsky.social @moffittnews.bsky.social oncodaily.com/blog/immunov... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Immunoverse #Podcast

Excited to be part of this #AACR25 (@theaacr.bsky.social @rickbuck.bsky.social) Social Media Ambassadorship!! Look out for updates on the #Tumor-microenvironment ( #TME )-relevant events and highlights. I’ll be posting from Sunday afternoon to midday Wednesday 😎

🚨The #AACR25 buzz is building! I’m thrilled to be a Social Media Ambassador for this year’s #AACR Annual Meeting. 👉🏼Please join me & all the ambassadors as we spotlight the exciting science. Research matters—and so does sharing it. Join the convo with @theaacr.bsky.social @rickbuck.bsky.social

Excited and honored to be a Social Media Ambassador for @theaacr.bsky.social #AACR25 Follow along with me here and on LinkedIn to experience the Annual Meeting with me starting this Friday in Chicago. Kicking off with #AACRAMC Grant Writing Workshop Friday afternoon! #AACRECR go.bsky.app/Jj6Efme

Abstracts are out for #ASCO25! 5000+ studies. 5 Plenary game-changers. @ascocancer.bsky.social @oncoalert.bsky.social @drchoueiri.bsky.social @ptarantinomd.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social

We're so excited about #AACR25 that we just created a starter pack for all their Social Media Ambassadors on #MedSky - almost all are here! Follow these leaders here for all the AACR lowdown: go.bsky.app/Jj6Efme

Hot off the press in @ascocancer.bsky.social journal JCO Oncology Advances: Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches ascopubs.org/doi/10.1200/... from our University of Minnesota group led by Dr. Ajay Prakash - #Immunoonc #immunotherapy

🚨🚨🚨Pleased to share our article in @ascocancer.bsky.social Ed book 👉🏼Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras 🦓🦓🦓 ascopubs.org/doi/10.1200/...

🚨 Hot off the press! 🚨 The @myesmo.bsky.social ESMO Precision Oncology Working Group, has unveiled key "Recommendations for structuring Molecular Tumour Boards (MTBs) in clinical practice", now published in ESMO's flagship journal Annals of Oncology 🧬🏥 www.annalsofoncology.org/article/S092...

📢 Agenda Spotlight: Plenary Session Are tumor-agnostic therapies the future of cancer treatment? Dr. @viveksubbiah.bsky.social will explore this evolving shift at **Great Debates in Solid Tumors**. Join the conversation: www.hmpglobalevents.com/gdst #GDST25 #MedicalEducation #GreatDebates #Cancer